EBT develops neuromodulation technologies that target the Saphenous nerve to treat pelvic health disorders, beginning with overactive bladder. By leveraging the nerve’s role in pelvic function, the company aims to move neuromodulation from a last‑line option to a primary therapy in patient care pathways.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
1OFounders
Product
Problem
Patients with pelvic health disorders such as overactive bladder often rely on pharmacologic or invasive surgical treatments that may have limited efficacy, undesirable side effects, or require extensive recovery time. Current neuromodulation options are typically reserved as last‑line therapies and involve complex, clinic‑based procedures.
Solution
EBT Medical has developed a clinical‑stage neuromodulation platform that targets the saphenous nerve, a key regulator of pelvic function. By delivering minimally invasive electrical stimulation to this peripheral nerve, the system aims to provide effective symptom relief earlier in the treatment pathway. The approach is designed for outpatient delivery, reducing procedural complexity and recovery time compared with traditional neuromodulation. EBT’s technology leverages precise nerve targeting and programmable stimulation parameters to modulate bladder activity and other pelvic functions. Clinical development focuses initially on overactive bladder, with the platform intended to expand to additional pelvic health indications.
Target Audience
Primary customers are urologists, urogynecologists, and pelvic health specialists seeking less invasive, early‑line treatment options for overactive bladder and related disorders.
Features
- Minimally invasive stimulation device engineered for outpatient implantation
- Targeted activation of the saphenous nerve to influence pelvic organ function
- Programmable stimulation protocols allowing individualized therapy settings
- Compact, patient‑friendly hardware suitable for office‑based procedures
- Clinical‑stage platform with ongoing trials to validate efficacy and safety